1. Leung, A. K. C., Leong, K. F. & Lam, J. M. Erythema nodosum. World J Pediatr 14, 548–554 (2018).
2. Algahtani, H., Shirah, B., Marghalani, S. & Algarni, A. Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate. Mult Scler Relat Disord 28, 155–158 (2019).
3. Pérez-Garza, D. M., Chavez-Alvarez, S., Ocampo-Candiani, J. & Gomez-Flores, M. Erythema Nodosum: A Practical Approach and Diagnostic Algorithm. Am J Clin Dermatol 22, 367–378 (2021).
4. Bosma, A. L., Stok, M. M., van der Valk, H. & van Praag, M. C. G. [Erythema nodosum as a reaction pattern: a broad spectrum of underlying causes]. Ned Tijdschr Geneeskd 161, D1061 (2017).
5. Weigle, N. & McBane, S. Psoriasis. Am Fam Physician 87, 626–633 (2013).
6. Dopytalska, K., Sobolewski, P., Błaszczak, A., Szymańska, E. & Walecka, I. Psoriasis in special localizations. Reumatologia 56, 392–398 (2018).
7. Furue, K. et al. Autoimmunity and autoimmune co-morbidities in psoriasis. Immunology 154, 21–27 (2018).
8. Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317 (2011).
9. Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54.e42; quiz e30 (2012).
10. Vavricka, S. R. et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 21, 1982–1992 (2015).
11. Greuter, T., Navarini, A. & Vavricka, S. R. Skin Manifestations of Inflammatory Bowel Disease. Clin Rev Allergy Immunol 53, 413–427 (2017).
12. Alinaghi, F. et al. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis 14, 351–360 (2020).
13. Egeberg, A., Thyssen, J. P., Burisch, J. & Colombel, J.-F. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study. J Invest Dermatol 139, 316–323 (2019).
14. Annese, V. A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease. Saudi J Med Med Sci 7, 66–73 (2019).
15. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018).
16. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 27, 1133–1163 (2008).
17. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).
18. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44, 512–525 (2015).
19. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol 40, 304–314 (2016).
20. Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 46, 1985–1998 (2017).
21. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50, 693–698 (2018).
22. Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 36, 1783–1802 (2017).